Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Nutra Pharma
Drug Discovery
Medical Devices
Newsroom
Investor Relations
Corporate Overview
Contact
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Welcome to Nutra Pharma

 
Drug Discovery and Medical Devices

Nutra Pharma Corp. operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. Additionally, the company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.

 
Interview on NBC News - Miami

NBC News - Miami aired an interview with CEO, Rik Deitsch discussing the use of cobra venom for the treatment of pain. The interview can be viewed on the following link: View here

 
 
Drug Discovery

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Nyloxin® is protected under patent #7,902,152, Use of cobratoxin as an analgesic. In December of 2014, the Company launched Pet Pain-Away - the first OTC product to treat pain in companion animals without side effects.

The Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Nutra Pharma has completed pre-clinical and animal models for their MS and HIV applications and are preparing to move into pivotal Phase II trials. Nutra Pharma's MS drug was recently granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis. .

Learn More
Nyloxin - Chronic Pain Relief
Pet Pain-Away
 
 
Shareholder Letter

CEO Rik Deitsch has posted a Letter to Shareholders: reviewing 2016 and looking forward to 2017. The letter can be viewed on the following link:Download here

 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


February 15, 2017
Nutra Pharma and Nyloxin Featured on NBC News-Miami


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics